Systemic lupus erythematosus


systemic lupus erythematosus: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None


diagram downward connector

Check conditions None


diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 M32
Hospital discharge: ICD-9 7100
Hospital discharge: ICD-8 7431
Cause of death: ICD-10 M32
Cause of death: ICD-9 7100
Cause of death: ICD-8 7431


diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9


diagram downward connector

Check minimum number of events None


diagram downward connector

Include endpoints None


diagram downward connector

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF2
Parent code in ICD-10 M30-M36
Name in latin Lupus erythematosus disseminatus (LED)

Summary Statistics

Key figures

All Female Male
Number of individuals 835 696 139
Unadjusted prevalence (%) 0.27 0.40 0.10
Mean age at first event (years) 45.45 44.62 49.64


Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.08 6.32 [4.05, 9.84] 3.9e-16 72
15 years 0.02 3.62 [2.33, 5.64] 1.2e-8 31
5 years 0.01 4.90 [2.76, 8.69] 5.4e-8 16
1 year 0.00 18.53 [9.47, 36.23] 1.4e-17 12

Age distribution of first events

Year distribution of first events

Cumulative Incidence


Index endpoint: M13_SLE – Systemic lupus erythematosus
GWS hits: 3

Survival analyses between endpoints


before Systemic lupus erythematosus
after Systemic lupus erythematosus

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Systemic lupus erythematosus